Font Size:
Site Colors:
Accesskey
S - Skip navigation
1 - Home page
4 - Search
Accessibility Statement
Contact us
News

Professor Pitcovski joins the European collaboration for developing vaccine adjuvants (ENOVA)

30 May, 2018

Professor Jacob Pitcovski, head of the Virology and Vaccine Development laboratory at MIGAL Galilee Research Institute has joined the European Network of Vaccine Adjuvants (ENOVA), which brings together European experts and stakeholders working in different areas of adjuvant and vaccine research and development, including both prophylactic and therapeutic applications as well as human and veterinary vaccines. ENOVA is funded by COST through the EU Framework Programme Horizon 2020 and is coordinated by the Vaccine Formulation Institute. The goals of the network are to facilitate communication and the exchange of information on adjuvants and vaccine formulation among its members, to ensure that new discoveries are widely disseminated so that their potential can be of optimal benefit, to promote the best use of existing adjuvant technologies, and to encourage and support the development of novel adjuvants and vaccines. Currently organizations from 28 countries joined ENOVA.

http://www.enova-adjuvant.eu

 

Students

Post-graduate and post-doctoral research training

Researchers

Laboratories and research projects

Business

Business opportunities and technology transfer